Thanks Willem Lybaert for taking pictures on all important oncology meetings :)

Have not read the paper yet, but am sure the RadOncs will react soon (as they did with Prospect in rectal) :)

🔥 Live vanuit Madrid met dagelijkse #ESMO2023 updates! 🇪🇸 Volg ons en blokkeer alvast 8/11 voor onze exclusieve Post-ESMO avond. Dé kans om dieper in de hoogtepunten te duiken en te netwerken. 👉medimix.be/post-esmo-2023… #MediMix #PostESMO2023 #ESMO2023 #oncologie #Oncology

MTAP loss in #BiliaryCancer in up to 20% of patients. Matched treatment study currently ongoing at our institution UZA (PI Hans Prenen) #ESMO2023

A panel of GI oncologists discuss the emerging data likely to impact clinical practice Watch the recorded discussion here 👉cor2ed.com/gi-connect/pro… Organised in partnership with eChinaHealth and GI CONNECT members Dominik Paul Modest Hans Prenen #MedEd

Another great submission for the Belgian Society of Medical Oncology #bsmoxmas Jumper Xmas Campaign by the oncology team from UZA Hans Prenen Timon Vandamme Laure-Anne Teuwen Annelies Verbiest #SevilayAltintas and others 🇧🇪 ⭐️🧑‍🎄🎄📸 StichtingtegenKanker

Alright! It’s that time of the year again. #ASCO24 is about to start. Here are our now classic rules of engagement. (Still don’t know the author to quote and credit). As usual Steven Vogl is exempt. @asco @oncoalert Nathan A. Pennell MD, PhD, FASCO Narjust Florez, MD, FASCO Dr. Estela Rodriguez Stephanie Graff, MD, FACP, FASCO Dr Sunil Verma Mike Thompson, MD, PhD, FASCO

If you are working in the field of GI Cancers and Global Oncology, we invite you to submit to the Article Collection "Treating GI cancers in resource-restricted countries" in Gastrointestinal Oncology: Management and Care. invt.io/1txbhft5wz9 Hans Prenen AORTIC

Who made this? 😂

Hoewel het voor darmkanker slechts in beperkt aantal gevallen (< 10%) werkt is #immuuntherapie toch zeer grote doorbraak in behandeling kanker! 🍀💪🏻 Prof Hans Prenen diensthoofd oncologie UZA UAntwerpen legt alles mooi uit in HLN.BE 😉 Stop Darmkanker 💙 #kennisdelen

Are you excited for #ESMO24 and the emerging data in GI oncology? Lower GI experts, Chiara Cremolini and Hans Prenen, will be covering the most hotly anticipated data, including the POD1UM-303 study Watch this space for more over the coming weeks!

Time to move away from radiotherapy in operable GEA #ESMO24 TOPGEAR ➡️ no survival benefit when RT added to periop chemo TOPGEAR + ESOPEC : both great trials with a definitive answer = no more RT ✅Great drugs in development - let's focus on systemic Rx for cure ESMO - Eur. Oncology

Impact of Exercise on Cancer Recurrence and Survival #ESMO24 OncoAlert #OncoAlert

📢 #ESMO24 concomitant paper: First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration. #ESMO24 Hans Prenen tinyurl.com/23btbhxd

📣 New #LowerGI cancer data from #ESMO24 📣 Profs. Chiara Cremolini & Hans Prenen joined us at the congress to share their insights on new data from POD1UM-303/InterAACT 2, RAMTAS/IKF643 & POCHI trials. 📺Watch their video update Supported by Bayer #Meded #CRC

🚨 New #LowerGI cancer data from #ESMO24 🚨 Profs. Chiara Cremolini & Hans Prenen joined us at the congress to each share their insights on new rectal & colorectal cancer data from NICHE-2, NICHE-3 & IMHOTEP trials. 📺Watch their video update Supported by Bayer #Meded #CRC

Hans Prenen #ESMO24 concomitant paper: Adrian Sacher, M.D. presents the First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor at today's Presidential Symposium Hans Prenen

Fantastic and insightful lecture from Prof. Hans Prenen about Use of immune therapies in GI cancer at #ESSO43 Practice changing news European Society of Surgical Oncology (ESSO) OncoAlert

Catch the #LowerGI oncology highlights from #ESMO24 📣 👉 ow.ly/3eYn50U563K Profs. Chiara Cremolini & Hans Prenen explore how new data from a range of trials could impact clinical practice. Don't miss out! Supported by an independent #MedEd grant from Bayer

1/4 Article of the month: First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration. Hans Prenen tinyurl.com/23btbhxd